Urinary proteomics based on capillary electrophoresis coupled to mass spectrometry in kidney disease

Methods in Molecular Biology

Volumn 919, Issue , 2013, Pages 203-213

  Albalat, Amaya ^a   Franke, Julia ^b   Gonzalez, Julien ^a   Mischak, Harald ^a,b   Zürbig, Petra ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MOSAIQUES DIAGNOSTICS GMBH   (Germany)

Author keywords

Capillary electrophoresis; Clinical proteomics; Mass spectrometry; Urine

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CAPILLARY ELECTROPHORESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; KIDNEY DISEASE; MASS SPECTROMETRY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEOMICS; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

EID: 84934443682     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-29-8_19     Document Type: Article

References (19)

1. Collins AJ et al (2011) US renal data system 2010 annual data report. Am J Kidney Dis 57(1 Suppl 1):A8
2. de Jong PE et al (2008) Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 3:616-623
3. El Nahas AM, Bello AK (2005) Chronic kidney disease: the global challenge. Lancet 365: 331-340
4. Atkins RC, Zimmet P (2010) Diabetic kidney disease: act now or pay later? Arch Cardiol Mex 80:44-47
5. Gansevoort RT et al (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80(1):93-104
6. Mischak H et al (2010) Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 17: 493-506
7. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. Am J Kidney Dis 39(2 Suppl 1): S1-S266
8. Fliser D et al (2007) Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 18:1057-1071
9. Rossing K et al (2008) The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2:997-1007
10. Theodorescu D et al (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7:230-240
11. Theodorescu D et al (2008) Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2:556-570
12. Mischak H et al (2009) Capillary electrophoresismass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 28:703-724
13. Metzger J et al (2009) Adapting mass spectrometry-based platforms for clinical proteomics applications: the capillary electrophoresis coupled mass spectrometry paradigm. Crit Rev Clin Lab Sci 46:129-152
14. McLerran D et al (2008) SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 54:53-60
15. Good DM et al (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9:2424-2437
16. Neuhoff N et al (2004) Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 18:149-156
17. Jantos-Siwy J et al (2009) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 8: 268-281
18. Dakna M et al (2010) Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 11:594
19. DeLeo JM (1993) Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. In: Proceedings second international symposium on uncertainty modeling and analysis, College Park, MD, USA. pp 318-325